Investigating of the side effects of covid-19 vaccines in Southern Iran: a cross-sectional study

Document Type : Original Articles

Authors

1 School of Medicine, Imam Khomeini Hospital, Jiroft University of Medical Sciences

2 Department of Health, Jiroft University of Medical University, Jiroft, Iran

3 Department of Public Health, School of Health, Khoy University of Medical Sciences, Khoy, Iran

4 Jiroft University of Medical University, Jiroft, Iran

5 Clinical Research Development Center of Imam Khomeini Hospital, Jiroft University of Medical Sciences, Jiroft, Iran

6 Clinical Research Development Unit, Imam Khomeini Hospital, Jiroft University of Medical Sciences, Jiroft, Iran

7 Postgraduate student of epidemiology،Clinical Research Development unit of Imam Khomeini Hospital, Jiroft University of Medical Sciences, Jiroft , Iran

8 Msc in a health education, Jiroft University of Medical Sciences, Jiroft, Iran

10.32592/ARI.2024.79.1.144

Abstract

The Covid-19 disease is a newly emerging disease, and the covid-19 vaccine is one of the necessities to prevent this disease. The present study aimed to Investigate the side effects of covid-19 vaccines in southern Iran. We used convenience sampling to conduct this cross-sectional study on 647 people living in cities under the coverage in southern Iran, Kerman. The data collection tool included a researcher-maid questionnaire of vaccine symptoms and signs. The results were analyzed by SPSS software version 24 and ANOVA, and chi-square tests. The mean age of the participants was 40.19±15.20. The results indicated that 431 people (66.6%) reported post-vaccination side effects, with 18.23% of them having severe side effects. We noticed the most severe side effects in AstraZeneca, Sinopharm, Sputnik, and Bharat. Fever, headache, and pain at the injection site were the most common side effects after vaccination respectively, which had a statistically significant relationship with all types of vaccines (P=0.001). The side effects differed in the types of vaccines and most of the vaccines had mild to moderate side effects. People with B blood type showed the most severe side effects while those with AB showed the lowest rate of side effects. Therefore, the injection of the AstraZeneca vaccine in blood group B should be done with more caution. And it is recommended more attention should be paid to blood groups B and A in the injection of Covid-19 vaccines. also, health officials and the government should plan appropriate educational strategies to increase public knowledge and the importance of vaccines in eradicating viral infections

Keywords

Main Subjects

References

References
1. Jung F, Krieger V, Hufert F, Küpper J-H. Herd immunity or
suppression strategy to combat COVID-19. Clinical
hemorheology and microcirculation. 2020;75(1):13-7.
2. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the
Progress and Challenges of Developing a Vaccine for
COVID-19. Frontiers in immunology. 2020;11:585354.
3. Cohen MS, Corey L. Combination prevention for COVID-19.
American Association for the Advancement of Science; 2020.
p. 551-.
4. Steele AD, Patel M, Parashar UD, Victor JC, Aguado T,
Neuzil KM. Rotavirus vaccines for infants in developing
countries in Africa and Asia: considerations from a World
Health Organization–sponsored consultation. The Journal of
infectious diseases. 2009;200(Supplement_1):S63-S9.
5. Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al.
The first month of COVID-19 vaccine safety monitoring—
United States, December 14, 2020–January 13, 2021.
Morbidity and mortality weekly report. 2021;70(8):283.
6. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of
COVID-19 vaccines in older people. Age and aging.
2021;50(2):279-83.
7. Anderson PO. Maternal vaccination and breastfeeding.
Breastfeeding Medicine. 2019;14(4):215-7.
8. Hughes BL, Swamy G, Eckert LON, Gyamq‐Bannerman C,
Turrentine M. Vaccinating pregnant and lactating patients
against COVID‐19. The American College of Obstetricians
and Gynecologists. 2021.
9. Mehrotra DV, Janes HE, Fleming TR, Annunziato PW,
Neuzil KM, Carpp LN, et al. Clinical endpoints for evaluating
efficacy in COVID-19 vaccine trials. Annals of internal
medicine. 2021;174(2):221-8.
10. Wang X. Safety and efficacy of the BNT162b2 mRNA
Covid-19 vaccine. N Engl J Med. 2021;384(16):1577-8.
11. Alessa MY, Aledili FJ, Alnasser AA, Aldharman SS, Al
Dehailan AM, Abuseer HO, et al. The side effects of covid-19
vaccines and their association with abo blood type among
general surgeons in Saudi Arabia. Cureus. 2022;14(3).
12. Hatmal MmM, Al-Hatamleh MA, Olaimat AN, Hatmal M,
Alhaj-Qasem DM, Olaimat TM, et al. Side effects and
perceptions following COVID-19 vaccination in Jordan: a
randomized, cross-sectional study implementing machine
learning for predicting the severity of side effects. Vaccines.
2021;9(6):556.
13. Aliberti SM, Schiavo L, Boccia G, Santoro E, Franci G,
Ruggiero A, et al. Gender and AB0 Blood Type Differences in
a Unicentric Group of University Professors in Southern Italy
Who Received the Vaxzevria COVID-19 Vaccine: A CrossSectional Survey of Vaccine Side Effects, Attitudes, and
Hesitation. Vaccines. 2022;10(3):373.
14. Chew NW, Cheong C, Kong G, Phua K, Ngiam JN, Tan
BY, et al. An Asia-Pacific study on healthcare workers’
perceptions of, and willingness to receive, the COVID-19
vaccination. International Journal of Infectious Diseases.
2021;106:52-60.
15. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E.
Early rate reductions of SARS-CoV-2 infection and COVID19 in BNT162b2 vaccine recipients. The Lancet.
2021;397(10277):875-7.
16. El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM,
Eid B, Almukadi H, et al. Minor to moderate side effects of
Pfizer-BioNTech COVID-19 vaccine among Saudi residents:
a retrospective cross-sectional study. International journal of
general medicine. 2021:1389-401.
158 Rostami Abusaeedi et al / Archives of Razi Institute, Vol. 79, No. 1 (2024) 149-158
17. Chapin-Bardales J, Gee J, Myers T. Reactogenicity
following receipt of mRNA-based COVID-19 vaccines. Jama.
2021;325(21):2201-2.
18. Kashte S, Gulbake A, El-Amin III SF, Gupta A. COVID-19
vaccines: rapid development, implications, challenges, and
prospects. Human cell. 2021;34(3):711-33.
19. Nikbakht G. Novel Insights into Infection and Immunity.
Iranian Journal of Veterinary Medicine. 2022;16(2):99-100.
20. Van Doremalen N, Lambe T, Spencer A, BelijRammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1
nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus
macaques. Nature. 2020;586(7830):578-82.
21. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et
al. Development of an inactivated vaccine candidate, BBIBPCorV, with potent protection against SARS-CoV-2. Cell.
2020;182(3):713-21. e9.
22. Wise J. Covid-19: European countries suspend use of
Oxford-AstraZeneca vaccine after reports of blood clots.
British Medical Journal Publishing Group; 2021.
23. Bhattacharjee S, Banerjee M. Immune thrombocytopenia
secondary to COVID-19: a systematic review. SN
comprehensive clinical medicine. 2020;2:2048-58.
24. Abu-Farha RK, Alzoubi KH, Khabour OF. Public
willingness to participate in COVID-19 vaccine clinical trials:
a study from Jordan. Patient preference and adherence.
2020:2451-8.
25. Allan JD, McMillan D, Levi ML, McMillan DT. COVID-19
mRNA Vaccination, ABO Blood Type and the Severity of
Self-Reported Reactogenicity in a Large Healthcare System: A
Brief Report of a Cross-Sectional Study. Cureus. 2021;13(12).
26. Enguita-Germán M, Librero J, Leache L, Gutiérrez-Valencia
M, Tamayo I, Jericó C, et al. Role of the AB0 blood group in
COVID-19 infection and complications: A population-based
study. Transfusion and Apheresis Science.
2022;61(3):103357. 
Archives of Razi Institute
Volume 79, Issue 1
January and February 2024
Pages 144-153

Files

Share

How to cite

Statistics